OH and the leaf of the kratom plant are not analogous, but as the former is a derivative of the latter, it has opioid-like qualities that make its susceptibility to abuse concerning.

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.